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The “ABC method” is a serum gastric cancer screening method, and the subjects were divided based on H. pylori serology and
atrophic gastritis as detected by serum pepsinogen (PG): Group A [H. pylori (−) PG (−)], Group B [H. pylori (+) PG (−)], Group
C [H. pylori (+) PG (+)], and Group D [H. pylori (−) PG (+)]. The risk of gastric cancer is highest in Group D, followed by Groups
C, B, and A. Groups B, C, and D are advised to undergo endoscopy, and the recommended surveillance is every three years, every
two years, and annually, respectively. In this report, the reported results with respect to further risk stratification by anti-H. pylori
antibody titer in each subgroup are reviewed: (1) high-negative antibody titer subjects in Group A, representing posteradicated
individuals with high risk for intestinal-type cancer; (2) high-positive antibody titer subjects in Group B, representing active
inflammation with high risk for diffuse-type cancer; and (3) low-positive antibody titer subjects in Group C, representing advanced
atrophywith increased risk for intestinal-type cancer. In these subjects, careful follow-upwith intervals of surveillance of every three
years in (1), every two years in (2), and annually in (3) should be considered.
1. Introduction
Clinicians usually regard the results of H. pylori serology
as a categorical variable (i.e., positive or negative), while
not considering the actual titer of anti-H. pylori antibodies.
Although the antibody titer itself suggests little clinically
useful information in individual cases, subjects at high risk
for gastric cancer can be detected effectively by evaluating
antibody titer results in populations stratified by the degree
of gastric mucosal atrophy. Many investigators have used
the “ABC method,” combining H. pylori antibody titers
and serum pepsinogen (PG) concentrations, to evaluate the
individual grade of atrophy and cancer risk [1–4]. Typically,
the significance of a serum screen for the measurement of
H. pylori antibody titer has been discussed in the context
of the ABC method. For example, “high-positive antibody
titer” subjects exhibit increased risk of diffuse-type gastric
cancer compared to populations without gastric atrophy, and
“low-positive antibody titer” subjects exhibit increased risk
of differentiated adenocarcinoma in populations with gastric
mucosal atrophy. These seemingly contradictory results have
been confirmed by several investigators, and the scientific
basis of these results has also been analyzed in detail [5–
8]. However, these data have been known only to a limited
number of investigators and clinicians and have not been
widely disseminated.
In the present review, we first describe the characteristics
of H. pylori antibody titers in the context of screening for
H. pylori infection, including consideration of the biological
meaning of the serum anti-H. pylori antibody titer. We then
discuss several reported results concerning anti-H. pylori
antibody titers. These data suggest the use (in daily clinical
practice) of an expanded ABCmethod to detect patients with
elevated risk for gastric cancer.
2. Characteristics of the H. pylori
Antibody Titer as a Screening Method for
H. pylori Infection
Measurement of the serum anti-H. pylori antibody titer is a
noninvasive, inexpensive, and readily available method for
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detection of H. pylori infection. Histology, culture, poly-
merase chain reaction (PCR), and the rapid urease test all
require biopsy and/or collection of specimens by endoscopy,
an invasive technique that is not suitable for mass screening
[9, 10].The urea breath test and stool antigen test are regarded
as noninvasive tests, but the results of both methods are
significantly affected by proton pump inhibitor therapy [11–
13]. However, validated serology tests can be used even in
patients being treated with proton pump inhibitors.
H. pylori strains possessing the cytotoxin-associated gene
A (CagA) protein, a well-known virulence factor, cause more
extensive inflammation and severe atrophy in gastric mucosa
than nonproducers [14, 15]. However, there is still controversy
regarding the significance of CagA serology, especially in East
Asia, wheremost strains ofH. pylori are CagA producers [16–
19]. Therefore, gastric cancer screening is usually performed
using theH. pylori antibody titer alone, except in limited areas
[20].
Burucoa et al. [21] investigated the accuracy of 29 different
serological tests and reported positive and negative predictive
values of 70% and 100%, respectively. In general, better
performance in serological screening depends on the use of
the appropriate antigens and adjustment of cut-off values
[22]. These considerations are among the disadvantages of
using serum H. pylori antibody as a screening test for gastric
cancer. Another disadvantage of using H. pylori antibody is
that serology alone presents a challenge in distinguishing past
and current infections [23]. The use of serology to identify
posteradicated cases is considered later in this review.
3. The ABC Method: Gastric Cancer
Screening Using H. pylori Antibody Titer
and Pepsinogen Levels
High seropositive rates for H. pylori antibody are observed
in East Asia, Eastern Europe, and parts of Central and South
America, all areas with populations that have high levels
of gastric cancer. Thus, in these regions, the anti-H. pylori
antibody titer alone is insufficient for use as a screening tool
for gastric cancer risk [24, 25]. For example, the frequency
of anti-H. pylori seropositivity in subjects born before 1950 is
reported to be over 70% in north Japan [26].
PG protein is classified into two types (PGI and PGII)
based on biochemistry and immunology. PGI is produced
by the chief cells in the gastric body; PGI levels decrease
proportionally with the progression of atrophy of the gastric
body. PGII is secreted by most parts of the gastric mucosa,
as well as by parts of the duodenum; PGII levels increase in
association with gastric mucosal inflammation regardless of
the degree of atrophy [27–29]. As a result, atrophic gastritis
can be diagnosed serologically by assaying the serum levels
of the two pepsinogen isozymes. Reductions in serum PGI
levels and in the serum PGI/II ratio are reliable markers for
atrophic gastritis; cut-off values of PGI≤70 ng/mL andPGI/II
ratio ≤3 have frequently been applied [30–32].
The European Society of Gastrointestinal Endoscopy has
proposed PG levels as a predictor of extensive atrophic
gastritis [33]. Miki reported that the odds ratio (OR) for
death from gastric cancer within 3 years after screening by
the PG method was 0.290 [1]. Several other well designed,
large-cohort studies have suggested an association between
PG levels and dysplasia/gastric cancer. Watabe et al. found
thatH. pylori-positive patients with PGI <70 and PGI/II ratio
<3 had a hazard ratio (HR) for gastric cancer of 6.0 [2];
under the same conditions, Yamaji et al. reported an HR of
6.2, and Yanaoka et al. reported an HR of 2.77 [34, 35]. The
preceding studies corresponded to Japanese populations, but
a report from Portugal showed consistent results in Western
individuals [36]. However, gastric cancers did develop in
a fraction (approximately 40%) of individuals who were
atrophy-negative as defined by PG levels; the pathological
characteristics of such cases revealed an unexpectedly high
percentage of diffuse cancer [35].
About half of the cases of diffuse cancer, of which the
prognosis is sometimes poor, cannot be detected by PG
methods.This observation represents a critical weak point in
mass screening by the PG method alone. Thus, a combined
analysis (the “ABCmethod”) incorporating the anti-H. pylori
antibody assay and mucosal atrophy (as determined by
serum PG) has been proposed to stratify the risk for the
development of gastric cancer [1–4, 37]. Notably, the ABC
method permits detection of gastric cancer in PG-negative
subjects, addressing the fact that most diffuse cancer is H.
pylori-positive but PG-negative. According to the original
ABC method (as proposed by Miki [1]), PG was defined
as “atrophic” when the criteria of both PGI ≤ 70 ng/mL
and PGI/II ≤3 were fulfilled. Under the ABC method, the
subjects were divided into the following 4 groups according
to the presence of atrophic gastritis identified by serum PG
and H. pylori seropositivity: Group A [H. pylori (−) PG
(−)], Group B [H. pylori (+) PG (−)], Group C [H. pylori
(+) PG (+)], and Group D [H. pylori (−) PG (+)]. Subjects
in Groups B, C, and D were advised to undergo H. pylori
eradication and endoscopic screening. The recommended
endoscopy intervals in Groups B, C, and D are every three
years, every two years, and every year, respectively, because
the risk of gastric cancer was highest in Group D, followed
by the risks in Groups C, B, and A [1, 4, 35]. Mizuno et al.
reported (usingGroupA as a reference) that theHR of gastric
cancer in Group B was 4.2, and those of Groups C and D
were 11.23 and 14.81, respectively [4]. The ABC method is
a screening strategy of “risk stratification” to identify high-
risk subjects. Using the ABC method, we can advise high-
risk subjects to undergo (1) regular endoscopic surveillance
and (2) eradication ofH. pylori infection. Subjects with a past
history of H. pylori eradication were strictly excluded from
screening by the ABC method; specifically, a subset of cases
with successful eradication showed negative antibody titers
in combination with increased PGI/II ratios, thus rendering
“false-negative” results [HP (−) PG (−)] in most eradication
cases. Kudo et al. reported that only 10.6% of all gastric cancer
patients would have been classified into Group A, indicating
that approximately 90% of cancer subjects would have been
regarded as positive by the ABC method [3].
Despite the apparent relationship between serum PG and
extensive atrophic gastritis, the association between endo-
scopic atrophic grade and histological diagnosis of atrophic
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gastritis remains controversial. Several investigators have
concluded that conventional white-light endoscopy cannot
accurately differentiate and diagnose atrophic gastritis [38,
39]. This inconsistency suggests that endoscopic findings are
insufficient for the accurate prediction of the grade of atrophy.
The essential weakness of the ABC method is the fact
that remarkably high percentages of subjects are classified
into Groups B–D, for whom endoscopy is indicated. One
study suggested that only 45–60% of Japanese subjects in
their 50s and 60s would be classified as Group A [26]. This
limitation should be recognized when using this method for
gastric cancer screening, especially in populations with high
endemic rates of H. pylori infection.
The other limitation of the ABC method is that hetero-
geneity of risk in each subgroup has been reported by several
investigators. All subjects in Group A do not show the same
risk for gastric cancer; the high-risk subjects in Group A can
be detected by stratification using antibody titers, and the
same heterogeneity is seen in Groups B and C. We will refer
to the details of the association between antibody titer and
risk stratification of each subgroup in the ABCmethod in the
following section.
4. Significance of the H. pylori Antibody
Titer in the ABC Method
4.1. Associations betweenAnti-H. pylori Antibody Titer and the
Degree of H. pylori Colonization. The immunopathological
response induced by H. pylori infection is hypothesized to
be dose-dependent. Higher bacterial counts induce intense
immune response, resulting in subsequent higher antibody
titers. However, genetic differences of each human host may
affect antibody levels to pathogens [40]. Immune suppression
by advanced cancer is another conceivable factor affecting
the antibody titer of H. pylori, although direct proof of
immune suppression in relation to the progression of gastric
cancer has not yet been demonstrated [41]. Nonetheless,
several investigators have inferred significant associations
between the anti-H. pylori antibody titer and H. pylori
density. Several investigators have found that the serological
absorbance index of IgG antibodies against H. pylori is
related to the density of antral H. pylori colonization and
polymorphonuclear cell infiltration [42, 43].The observation
of significant decreases in H. pylori antibody titers following
successful eradication implies the existence of a quantitative
relationship [44]. Marchildon et al. reported that the mean
decrease in IgG titer of H. pylori antibody at 6 months is
approximately 40% [45]. Considered together, these findings
indicate that the H. pylori antibody titer might be used to
estimate the density of H. pylori in whole gastric mucosa.
4.2. Significance of “Low” Antibody Titer of H. pylori in
Gastric Cancer Screening
4.2.1. Spontaneous Disappearance of H. pylori after Progression
of Atrophic Gastritis in ABC Method-Defined Groups C and
D. Chronic infection by H. pylori leads to H. pylori-related
gastritis, which starts in the antrum and expands proximally
towards the gastric body [46, 47]. Several investigators
analyzing the association between gastric cancer develop-
ment and H. pylori antibody titer demonstrated that this
association is not proportional [35, 48, 49]. Multiple studies
have reported that gastric cancer risk is elevated in subjects
who display low-titer seropositivity for H. pylori antibody in
combination with advanced mucosal atrophy (as determined
by the PG level) (i.e., GroupC in the ABCmethod) compared
to high-titer subjects [5, 35, 50, 51]. Yanaoka et al. first referred
to the significance of a “low-positive titer” in screening for
gastric cancer. Those authors reported that the hazard ratio
(HR) of overall cancer incidence in low-positive antibody
titer subjects with serological atrophywas significantly higher
(HR = 11.4) than in those with high-positive antibody titers
(HR = 6.7), suggesting an increased risk in “low titer”
patients, especially atrophic subjects [35]. Based on a case-
controlled study, Fujioka et al. reported that the median
serum antibody titer was lower in cancer cases than in control
cases, such that high-positive titer patients have a reduced
risk for gastric cancer (OR = 0.39) [50]. Note, however,
that that study population was not confined to subjects
with atrophy (i.e., not limited to Group C only). In a large
study (with >36,000 participants), Tatemichi et al. clearly
demonstrated an association between a low-seropositive H.
pylori antibody titer and a high incidence of gastric cancer
among PG-positive subjects [5]. That paper reported that,
among the severely atrophic subjects in Group C, the ORs
of cancer incidence (using Group A as reference) in low-
positive titer andhigh-positive titer subjectswere 14.9 and 8.3,
respectively, suggesting that the risk in low-positive titer cases
was almost double that in high-positive titer cases.That paper
also analyzed the risk of intestinal- and diffuse-type cancers
in “low-positive antibody titer” patients, demonstrating a
significant association between the risk of cancer and “low-
positive antibody titer” in intestinal-type cancer, but not in
diffuse-type cancer.
To make sense of these results, we need to understand
the environment suitable for survival of H. pylori in gastric
mucosa. H. pylori can survive in gastric epithelial cells; thus,
the loss of gastric epithelial cells after the progression to
advanced atrophic gastritis with intestinal metaplasia can
lead to spontaneous elimination of H. pylori [52, 53]. Thus,
after infection withH. pylori in childhood, the bacterial den-
sity is expected to increase; presumably during this period,
atrophy is limited to the antrum. Subsequently, a subset of
these cases will progress to further atrophy of the gastric
corpus; in these individuals,H. pylori numbers will gradually
decrease, with some of these cases developing intestinal-type
cancer in accordance with Correa’s hypothesis [46]. In our
experience, approximately 20%of subjects older than 60 years
who are classified as Group C (by the ABC method) show
low-positive H. pylori antibody titers (data not shown). This
observation suggests that most subjects in Group C do not
show progressive atrophy. Thus, for Group C patients, an
elevated risk of gastric cancer development is indicated by the
combination of both lowH. pylori antibody titer andmucosal
atrophy.
We have also focused on the role of antibody titer, with
data suggesting the significance of “low-positive titer” in
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subjects with atrophy. Specifically, our investigation of the
association between the H. pylori antibody titer and fasting
gastric pH revealed that impairment of acid secretion (a
functional indicator of gastric atrophy) was most severe in
patients with atrophic mucosa [PG(+)] and low-positive H.
pylori antibody titer (i.e., Group C as defined by the ABC
method) [54]. Our findings suggest that these subjects have
an extremely high risk for gastric cancer, an interpretation
that is consistent with previous reports, including Tatemichi
et al. [5]. These results may also explain the occurrence of
gastric cancer in ABC-defined Group D [PG(+), HP (−)]: H.
pylori may be “disappearing” from the mucosa in a state of
advanced atrophy [5]. Presumably, when the antibody titer
in Group C fell below the cut-off value, those cases were
classified as Group D (seronegative). Comparison of severely
atrophic H. pylori-negative cases (Group D) to less atrophic
H. pylori-positive cases (Group C) yielded respective HR
values in gastric cancer of 131.98 versus 2.77 in Yanaoka et
al. [35] and of 61.85 versus 14.85 in Ohata et al. [55]. The
European Society of Gastrointestinal Endoscopy also noted
that the spontaneous disappearance of H. pylori antibody
was associated with the progression to severe gastric mucosal
atrophy [33].
Consequently, the consensus of opinion now holds that
subjects harboring the combination of low-positive H. pylori
antibody titer and atrophic gastric mucosa are at higher risk
for gastric cancer than subjects with a high-positive antibody
titer, especially intestinal-type cancer. We recommend the
following two management steps for these subjects: eradica-
tion of H. pylori and short-interval endoscopic surveillance.
Eradication of H. pylori is usually advised in the ABC
method; however, we recommend reconfirming it, especially
in subjects with a low-positive antibody titer in Group C. In
Group D, infection ofH. pylori should be strictly investigated
using other methods (urea breath test, stool antigen, etc.),
and it should be eradicated if positive. Based on the ABC
method, the interval for endoscopy is every two years in
Group C and every year in Group D; however, we consider
it desirable for patients with a low-positive antibody titer in
GroupC to undergo endoscopy every year, based on the result
of Tatemichi et al. that the HR of gastric cancer in subjects
with a low-positive antibody titer is twice that of those with a
high-positive antibody titer.
Because the normal value of H. pylori antibody titer is
different with each EIA kit, optimization of the cutoff value
used to divide the “low-positive” and “high positive” subjects
should be considered. Previous reports by Tatemichi et al.
[5] and our own [54] set the cutoff point to 57.7U/mL and
50U/mL for the low-positive and high-positive antibody titer
groups using the EIA kit of E plate, Eiken, ensuring the ratio
of both group becomes about half of allH. pylori-seropositive
subjects. Thus, we advocate that H. pylori-seropositive cases
should be subdivided into two groups, low-positive and high-
positive groups, and the cutoff value should be set to the
points at which about one half of H. pylori-seropositive
subjects are classified into each group.
4.2.2. Disappearance of H. pylori after Unexpected Eradication
by Antibiotics and Its Significance in Group A. Dissemination
of antimicrobial resistance induced by inappropriate use or
abuse of antibiotics is a global public health problem [56].
The reported rate of inappropriate antibiotic use in hospitals
ranges from 26% to 57% [57, 58], and the adherence rates
for drug selection and treatment duration are relatively low,
with rates as low as 38% even in Japan [59]. The failure
of conventional triple therapies to eradicate H. pylori has
been attributed primarily to bacterial resistance to one of
the most commonly used antibiotics, clarithromycin [60–
62]. The prevalence of clarithromycin resistance in the USA
has increased from 9.1% in 2009-2010 to 24.2% in 2011–2013
[57]. In Italy, the prevalence of clarithromycin resistance has
increased rapidly, doubling from 10.2% to 21.3% between
1990 and 2005 [62]. The rate of clarithromycin resistance at
younger ages (in individuals under 30 years) was reported to
be as high as 57% in Japan and 7.4% in USA [63, 64].
These findings suggest the possibility that a large fraction
of H. pylori subjects achieved unexpected and complete
H. pylori eradication after exposure to antibiotics for the
treatment of other infectious diseases. The ABC method
specifies the exclusion of subjects with a past history (as
determined by medical interview) of eradication of H. pylori
infection. However, subjects with unexpected eradication
cannot be excluded completely, and such subjects are at risk
for developing cancer as a result of a previous H. pylori
infection.
The Shandong Intervention Trial is the first single trial
indicating that the incidence of gastric cancer was signifi-
cantly reduced inH. pylori-eradicated cases, with anORof 0.6
after a follow-up period of 14.3 years [65]. Additional reports,
including meta-analyses, have demonstrated that the eradi-
cation of H. pylori decreases the possibility of future cancer
development by 30% [66–68]. These findings, however, sug-
gest that the future cancer risk is not completely eliminated.
Although several investigators have reported a low incidence
of gastric cancer in subjects classified into Group A [55, 69],
other investigators recently reported that approximately 2–
10%of gastric cancer patientswere serologically classified into
“Group A.” Most of these subjects were hypothesized to be
“unexpectedly and successfully eradicated cases,” given that
subjects with a past history of eradication are excluded from
screening by the ABC method but nonetheless have a risk of
later development of gastric cancer [70–73].
The pathological characteristics of cancer in patients
classified in Group A are controversial. Boda et al. reported
that 92.6% of gastric cancer cases classified in Group A are
intestinal-type; however, those authors investigated a limited
number of early-stage subjects treated by endoscopy [70].We
also found that 90% of cancer in the subjects in Group A was
the intestinal-type. Meanwhile, Kato et al. reported that only
33% of cancer cases in Group A were intestinal-type [72]. It is
speculated that diffuse-type cancer arises from truly negative
cases, and intestinal-type cancer arises from posteradicated
cases. However, the details of the pathological characteristics
of cancer in Group A will need to be investigated further. In
this context, “successfully eradicated cases” are misclassified
as Group A in the ABCmethod, and so these patients are not
regarded as candidates for endoscopy, despite an elevated risk
for subsequent transformation. Histological damage from
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undiagnosed but resolvedH. pylori infections is hypothesized
to be the main source of gastric neoplasia amongmembers of
Group A.
We have recently been investigating predictive factors
associated with gastric cancer in subjects who are negative for
serum H. pylori antibody with normal PG status (i.e., Group
A).We found that high-negative antibody titer (≥3U/mL and
<10U/mL) is the significant factor for the prediction of gastric
cancer in Group A (unpublished data). Although significant
decreases in antibody titer after successful eradication have
been reported [44, 45], complete seronegativity (antibody
titer of zero) is typically not observed. We speculate that this
persistence of a nonzero titer after eradication is the reason
why lowering the cut-off value of the antibody titer is effective
for the detection of neoplasia in Group A. Clinicians should
be aware that a subset of serologically H. pylori-negative
subjects are not true-negative cases but eradicated cases, even
in patientswhodeny a past history of eradication treatment. It
should also be noted that there is a possibility thatH. pylori is
not completely eradicated in serologically H. pylori-negative
subjects; eradication is necessary in such cases.
Patients with unexpected eradication can also be detected
by a characteristic change in serum PG. These individuals
correspond to cases previously reported to possess “increased
PGI/II ratios and decreased PGI levels,” who were regarded
as “normal” by the PG test [74, 75].
Based on the ABC method, subjects in Group A are not
usually advised to undergo second-level diagnostic assess-
ment using endoscopy; however, we consider that Group A
subjects with a high-negative antibody titer should undergo
endoscopy at least every three years, as in Group B. We also
recommend investigating the H. pylori infection status in
these subjects, and if H. pylori is detected by methods other
than serology (urea breath test or stool antigen), we consider
that it should be eradicated.
We advocate that H. pylori seronegative cases should be
divided into two subgroups, low-negative and high-negative
groups, with the ABC method. Optimization of the cut-
off value should be considered to identify subjects with a
“high-negative” H. pylori antibody titer, which corresponds
to 3U/mL (3U/mL is the minimum determination limit and
10U/mL is the recommended cutoff point) when using E
plate, Eiken in our examination. We recommend resetting
the cut-off value to the lower limit of each EIA kit and to
evaluate the ratio of neoplasia cases in group A defined by
strict criteria.
4.2.3. Classification of Subjects with Negative H. pylori Anti-
body Titers May Be Assisted by Serological Characterization
of the Titer. Given the influence on the H. pylori antibody
titer of the above-mentioned mechanisms, we propose clas-
sifying subjects negative for H. pylori antibody titer into
the following three categories: (1) truly infection-negative;
(2) infection-positive with deep progression of atrophic
gastritis (in which antibody titer was normalized following
spontaneous disappearance of H. pylori from the gastric
mucosa); and (3) infection-positive, in which infection has
been successfully eradicated. The eradicated cases (Class 3)
are further subdivided into two categories: subjects in whom
infection is eradicated by conventional triple therapy and sub-
jects in whom infection is unexpectedly eradicated without a
past history of eradication therapy.
Class 1 (infection-negative) individuals are “true-
negative” cases. Most infection-negative cases will exhibit
normal PG levels, and so would be categorized as Group
A [H. pylori (−) PG (−)] according to the ABC method.
Members of Class 1 typically will exhibit high PGI levels and
are at extremely low risk for future gastric carcinogenesis.
Class 2 (infection-positive with deep progression of
atrophic gastritis) cases will exhibit normalized antibody
titers and PG-positive status, and so would be categorized as
GroupD [H. pylori (−) PG(+)] according to theABCmethod.
Members of Class 2 are at extremely high risk for intestinal-
type gastric carcinogenesis.
Class 3 (infection-positive but successfully eradicated)
cases will yield normal PG levels, and sowould be categorized
as Group A [H. pylori (−) PG (−)] according to the ABC
method. Members of Class 3 have a chance of developing
intestinal-type gastric cancer.
4.3. Significance of “High” Antibody Titer of H. pylori in
Gastric Cancer Screening. About 20–30% of stomach cancers
in Western countries develop from nonatrophic stomach,
and the major histopathological type of these cancer cases
has been reported to be “diffuse-type” [76, 77]. The most
significant characteristic of diffuse-type cancer is a higher
malignant potential than the intestinal type. The inflam-
mation of gastric mucosa induced by H. pylori infection
is postulated to directly induce this diffuse-type cancer
without passing through the well-known sequence of atrophy
to metaplasia to dysplasia to cancer. Inflammation-induced
DNA methylation has been implicated in the induction of
diffuse-type gastric cancer [78]. Consequently, diffuse-type
cancer typically does not show advanced atrophy, and this is
the reason why PG level, a reliable marker of gastric atrophy,
cannot detect this type of cancer effectively. Thus, the risk
factors for developing cancer among nonatrophic stomach
cases include high PGII level and highH. pylori antibody titer,
both of which reflect active gastric mucosal inflammation
[79].
The association between diffuse-type cancer and a “high-
positive” titerH. pylori antibody has been reported by several
investigators. Tatemichi et al. conducted a case-controlled
study using gastric cancer cases andmatched control subjects,
and they demonstrated that high-titer patients have the
highest risk for diffuse cancer development [80].Watanabe et
al. recently elucidated, for the first time, the risk for diffuse-
type gastric cancer in PG-negative individuals with high-titer
H. pylori antibody (ABC method Group B). By performing
annual endoscopies in H. pylori-positive subjects who did
not exhibit chronic atrophic gastritis (i.e., Group-B subjects),
Watanabe et al. demonstrated that cancer incidence was
significantly higher in the H. pylori high-titer group than in
the low-titer group, obtaining an HR of 6.51 [7]. That study
also reported a marked increase in cancer development (at
1524/100,000 person-years) in Group B subjects harboring
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high-titer antibody and high PGII levels (PGI >50 ng/mL and
PGI/II ratio ≤3). Other investigators have reported similar
results [35]. Yoshida et al. recently reported that the HR
values of diffuse-type cancer in high-titer subjects stratified
by PGII (<30 ng/mL and >30 ng/mL) were 3.8 and 8.5,
respectively, when cancer incidence in low-titer subjects with
PGII <30 ng/mLwas used as in [8]. In our ownwork, we have
observed that approximately 15% of Group B subjects over
the age of 60 years show high H. pylori antibody titers (data
not shown), suggesting that most subjects in Group B do not
show progressive mucosal inflammation.
The high-positive anti-H. pylori antibody titer in Group
B represents a risk factor for future gastric carcinogenesis,
especially for diffuse-type cancer. Considering the high
prevalence of diffuse-type cancer in Western countries, the
combination of increased H. pylori antibody titer and high
PGII levels is expected to be of use as a serum (noninva-
sive) screen for gastric cancer among Western populations.
Because H. pylori eradication reduces the cancer risk more
effectively in subjects without extensive chronic atrophic gas-
tritis [81], eradication of H. pylori infection in these subjects
is strongly recommended for prevention of gastric cancer in
these patients in Group B. Although eradication is usually
advised after conducting the ABC method, we recommend
reconfirming eradication in these subjects. Based on the ABC
method, endoscopy every three years is recommended for
the subjects in Group B; however, the HR of subjects with a
high-positive antibody titer in Group B is two to three times
higher than of those with high-positive titers [8], and thus
the HR of cancer in these high-positive subjects is estimated
to be similar to that of Group C.Thus, meticulous endoscopic
surveillance should be performed every two years in Group
B subjects with a high-positive antibody titer.
The cutoff value should be set so that one half of
H. pylori-seropositive subjects are classified to each of the
“low-positive” and “high-positive” groups, as referred to in
Section 4.2.1.This value is 50U/mLwhen using E plate, Eiken
based on our investigations (10U/mL is the recommended
cutoff point).
5. Natural History of H. pylori-Positive
Subjects and the Relationship with the H.
pylori Antibody Titer
The natural history of subjects with H. pylori infection has
usually been discussed in the context of Correa’s hypothesis
[46], which postulates that gastric carcinogenesis occurs as
a continuous process beginning with superficial gastritis and
proceeding throughmetaplasia and dysplasia before reaching
adenocarcinoma. However, few investigators have reviewed
the natural history of H. pylori-infected subjects from the
standpoint of the H. pylori antibody titer profile.
Here, we present the “typical” natural history ofH. pylori-
positive subjects and the associations withH. pylori antibody
titer. We believe that readers will gain an overview of the

















Figure 1: Time course of changes in theH. pylori antibody titer inH.
pylori-infected subjects without significant progression of mucosal
atrophy (Grade B in the ABC method). The antibody titer does not
show significant change in most Group B cases. An increase in the
H. pylori antibody titer is observed in a subset of these patients with
progressivemucosal inflammation; such cases have an increased risk
for diffuse-type cancer.Thus, subjects with a high-positive antibody
titer should be considered at high risk for future development of
diffuse-type gastric cancer.
Subjects with progressive atrophy
Subjects without progressive atrophy
Time
Cut-off value







Figure 2: Time course of changes of the H. pylori antibody titer
in H. pylori-infected subjects with progression of mucosal atrophy
(Grade C in the ABC method). In Group C, the antibody titer does
not change significantly (in contrast to the pattern in most Group B
cases). However, in a subset of Group C cases, the antibody titer of
H. pylori decreases gradually due to shrinkage of the effective area
of the gastric mucosa as a result of the progressive atrophy induced
by H. pylori infection. Thus, Group C subjects with low-positive H.
pylori IgG titers exhibit an elevated risk for intestinal-type gastric
cancer.
Figures 1–4 show a schematic view of the four patterns of
the serial change of H. pylori antibody titer.
Figure 1 shows the typical pattern of H. pylori antibody
titer in subjects who do not show significant progression
of damage to the gastric mucosa despite infection with H.
pylori. This subset of patients is classified as Group B in the
ABC method. In most of these cases, antibody titer does
not show significant change. However, an increase in H.
pylori antibody titer is observed in a subset of these cases,
specifically those with progressive mucosal inflammation,
who have an increased risk for diffuse-type cancer. Thus, the
subjects in Group B are subdivided into the following two
subgroups: subjects with a low antibody titer (at low risk










Figure 3: Time course of changes of theH. pylori antibody titer inH.
pylori-infected subjects with severe progression of mucosal atrophy
(GradeD in theABCmethod). Subjects inGroupD show significant
“advanced” progression of atrophy; members of this group become
seronegative for H. pylori antibody titer following the spontaneous
disappearance of H. pylori from gastric mucosa. This subset of
patients would be classified originally as Group B and then as Group
C as atrophy progresses and finally as Group D when the antibody
titer falls below the cut-off value (converting to antibody-negative
status, as indicated by the arrow). Approximately 1% of all subjects
in Japan will be classified as Group D, suggesting that only a limited















Figure 4: Time course of changes of the H. pylori antibody titer in
successfully eradicated cases (classified as Grade A, although these
cases should be excluded bymedical interview in the ABCmethod).
After successful eradication ofH. pylori, the antibody titer decreases
due to disappearance ofH. pylori from the gastric mucosa, and from
that point, the degree of atrophic grade progresses no further. Thus,
a defined risk for gastric cancer persists throughout the lifetime of
these patients, because a certain degree of gastric mucosal atrophy
exists even after infection eradication. Therefore, eradicated cases
should not be included as candidates in the ABC method, and they
will require surveillance by endoscopy.
titer due to advanced mucosal inflammation (at high risk for
future gastric cancer) (Figure 1).
Figure 2 shows the typical pattern of H. pylori antibody
titer in subjects who show significant progressive atrophy of
the gastric mucosa. This subset of patients is classified as
Group C in the ABC method. In some cases, the antibody
titer will not change significantly (unlike the situation in
Group B); however, in other cases, the H. pylori antibody
titer will decrease gradually due to shrinkage of the effective
area of gastric mucosa by H. pylori infection, although the
degree of atrophy will differ depending on the pathogenicity
of specific H. pylori strains and the immunological response
of each human host. Subjects with a lower H. pylori IgG titer
have a higher risk for gastric cancer than high-positive titer
subjects in Group C, as reported by Tatemichi et al. [5]. We
have confirmed this pattern in our own work investigating
the association between gastric acidity andH. pylori antibody
titer [54].
Figure 3 shows the typical pattern of the H. pylori
antibody titer in subjects who show significant “advanced”
progression of atrophy of gastric mucosa, with the H. pylori
antibody titer becoming negative following the spontaneous
disappearance of H. pylori from the gastric mucosa. This
subset of patients is classified as GroupD in theABCmethod.
About 99% of H. pylori-infected patients are classified into
Groups A, B, and C; the remaining approximately 1% of
H. pylori-infected cases are defined as belonging to Group
D. Specifically, separate reports by Miki and Yoshida et al.
reported the incidence of Group D as 0.66% (33 of 5209
subjects) and 0.71% (33 of 4655 subjects), respectively [1, 8]. A
limited number ofH. pylori-infected patients show extremely
deep progression of atrophy with negative conversion of H.
pylori antibody titer; most of these cases are hypothesized to
originate as low antibody titer Group C subjects. Members of
this class show high risk for gastric carcinogenesis, especially
differentiated adenocarcinoma.
Figure 4 shows the typical pattern of the H. pylori
antibody titer in subjects from whom H. pylori has been
eradicated, irrespective of whether elimination resulted from
treatment with conventional triple therapy or by “unex-
pected” eradication. This subset of patients is sometimes
misclassified as Group A in the ABC method; however, the
risk for the development of gastric cancer is comparable to
that in Group B. These subjects are not true-negatives for
H. pylori and thus should be distinguished from Group A.
We have demonstrated [54] that a high-negative H. pylori
antibody titer is a significant predictor of gastric neoplasia in
GroupA cases.We advocate lowering the cut-off value for the
H. pylori antibody titer, a step that would permit detection of
such “eradicated” cases.
6. Modified Schematic Diagram of the ABC
Method Considering the Significance of
the H. pylori Antibody Titer
Figure 5 shows the generally accepted classification of the
ABC method, in which the cases are divided into the
following four groups: GroupA [H. pylori (−) PG (−)], Group
B [H. pylori (+) PG (−)], Group C [H. pylori (+) PG (+)],
and Group D [H. pylori (−) PG (+)]. The incidence of gastric
cancer increases in a stepwise and significant manner from
A to D, as the color gradation shows the increasing risk for
gastric cancer.
Figure 6 shows amodified schematic diagram of the ABC
method incorporating the antibody titer as a continuous
variable, as proposed in this review. The color gradation
shows the risk for gastric cancer.The horizontal axis showing
H. pylori serology is transformed from a categorical variable
(i.e., positive or negative) to a continuous variable of antibody
titer. For Group A, we demonstrated that the incidence of
intestinal-type gastric neoplasia in the high-negative anti-
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Figure 5: ABC method classification by H. pylori serology and
pepsinogen status. Subjects are divided into four groups according
to the serology of H. pylori antibody and pepsinogen (PG) status:
Group A [H. pylori (−) PG (−)], Group B [H. pylori (+) PG (−)],
Group C [H. pylori (+) PG (+)], and Group D [H. pylori (−) PG
(+)]. The incidence of gastric cancer increases in a stepwise and
significant manner from A to D. The color gradation shows the risk
for gastric cancer.
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Figure 6: Modified schematic diagram of the ABC method consid-
ering the antibody titer as a continuous variable. Groups A, B, and
C can each be divided into two subgroups based on antibody titer.
The color gradation shows schematically the risk for gastric cancer.
In Group A, the incidence of gastric cancer in the high-negative
antibody subset is higher than that in the low-negative antibody titer
subset. In Group B, the incidence of gastric cancer (typically diffuse-
type cancer) in the high-positive titer antibody subset is higher than
that in the low-positive titer antibody subset. In Group C, the HR
of gastric cancer (typically intestinal-type cancer) is higher in low-
positive titer subjects than in high-positive titer subjects.
titer subset [54]. For Group B, the incidence of diffuse-
type gastric cancer in the high-titer antibody subset was
elevated compared to the cases that were H. pylori-positive
but possessed low antibody titer [7]. For Group C, the HR of
intestinal-type gastric cancer was higher in low-titer subjects
than in high-titer subjects.
7. Conclusions
Clinicians should consider the meaning of the antibody titer
when interpreting a patient’s status as defined by the ABC
method. The risk for gastric cancer in subjects classified into
each group is not the same, but clinicians should understand
the fact that some high-risk populations detected by antibody
titer stratification are included. We recommend dividing the
cases by antibody titer into four subgroups, not two (negative
and positive) subgroups: low-negative, high-negative, low-
positive, and high-positive. One example of the range of
each subgroup is <3U/mL, 3–10U/mL, 10–50U/mL, and
>50U/mL, respectively. We especially advocate attention
to the antibody titer itself in the following three clinical
conditions.
The first condition occurs when a high-negative antibody
titer is observed in PG-negative cases (Group A). Most of
these subjects are posteradicated cases who have an elevated
risk for developing gastric cancer. Lowering the cut-off value
of the H. pylori antibody titer to the lower limit of each EIA
kit will be important for the detection of these high-risk
eradicated cases.
The second condition occurs when a high-positive anti-
body titer is observed in PG-negative cases (Group B). These
subjects exhibit active mucosal inflammation and have an
elevated risk for developing diffuse-type cancer.
The third condition occurswhenpositive but low-positive
antibody titer is observed in subjects with mucosal atrophy
(as defined by PG levels) (Group C). These subjects have
severe progressive atrophy with a high risk for intestinal-
type gastric cancer.The cutoff values of low and high-positive
antibody titers should be set at values that put about half of
the seropositive subjects into each subgroup.
In these cases, we consider that the interval of endoscopic
surveillance should be shorter than the interval recom-
mended by the ABC method: every three years for subjects
with a high-negative antibody titer in Group A; every two
years for subjects with a high-positive antibody titer in Group
B; and every year for subjects with a low-positive antibody
titer in Group C. Moreover, eradication of H. pylori is also
strongly recommended to prevent future development of
gastric cancer. Even in subjects who are serologically negative
but have a high-negative antibody titer (Group A), H. pylori
should be evaluated by other methods, and it should be
eradicated if the results of the other evaluation methods are
positive.
There is a possibility that gastric cancer screening solely
by the ABC method is insufficient for the above-mentioned
limited number of cases detected only by considering anti-
body titer. We believe that focusing on the serum H.
pylori antibody titer as a quantitative (rather than qualita-
tive/categorical) parameter will enhance the power of the
ABC method as a screen for future risk for gastric cancer.
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